---
document_datetime: 2025-11-23 08:00:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/leganto.html
document_name: leganto.html
version: success
processing_time: 0.1098425
conversion_datetime: 2025-12-27 09:43:21.480896
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Leganto

[RSS](/en/individual-human-medicine.xml/65422)

##### Withdrawn

This medicine's authorisation has been withdrawn

rotigotine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 December 2021, the European Commission withdrew the marketing authorisation for Leganto (rotigotine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, UCB Pharma S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Leganto was granted marketing authorisation in the EU on 16 June 2011 for the treatment of restless legs syndrome and Parkinson´s disease. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016.

Leganto was a duplicate of Neupro, which is marketed in several EU countries.

The European Public Assessment Report (EPAR) for Leganto is updated to indicate that the marketing authorisation is no longer valid.

Leganto : EPAR - Summary for the public

English (EN) (671.07 KB - PDF)

**First published:** 23/06/2011

**Last updated:** 18/02/2022

[View](/en/documents/overview/leganto-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-270)

български (BG) (734.38 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/bg/documents/overview/leganto-epar-summary-public_bg.pdf)

español (ES) (663.12 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/es/documents/overview/leganto-epar-summary-public_es.pdf)

čeština (CS) (714.3 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/cs/documents/overview/leganto-epar-summary-public_cs.pdf)

dansk (DA) (640.39 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/da/documents/overview/leganto-epar-summary-public_da.pdf)

Deutsch (DE) (665.23 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/de/documents/overview/leganto-epar-summary-public_de.pdf)

eesti keel (ET) (638.45 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/et/documents/overview/leganto-epar-summary-public_et.pdf)

ελληνικά (EL) (1.43 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/el/documents/overview/leganto-epar-summary-public_el.pdf)

français (FR) (664.75 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fr/documents/overview/leganto-epar-summary-public_fr.pdf)

italiano (IT) (662.79 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/it/documents/overview/leganto-epar-summary-public_it.pdf)

latviešu valoda (LV) (713.01 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lv/documents/overview/leganto-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (685.97 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lt/documents/overview/leganto-epar-summary-public_lt.pdf)

magyar (HU) (707.81 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/hu/documents/overview/leganto-epar-summary-public_hu.pdf)

Malti (MT) (715.54 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/mt/documents/overview/leganto-epar-summary-public_mt.pdf)

Nederlands (NL) (665.29 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/nl/documents/overview/leganto-epar-summary-public_nl.pdf)

polski (PL) (736.52 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pl/documents/overview/leganto-epar-summary-public_pl.pdf)

português (PT) (639.58 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pt/documents/overview/leganto-epar-summary-public_pt.pdf)

română (RO) (685.57 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/ro/documents/overview/leganto-epar-summary-public_ro.pdf)

slovenčina (SK) (737.01 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sk/documents/overview/leganto-epar-summary-public_sk.pdf)

slovenščina (SL) (727.4 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sl/documents/overview/leganto-epar-summary-public_sl.pdf)

Suomi (FI) (662.36 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fi/documents/overview/leganto-epar-summary-public_fi.pdf)

svenska (SV) (662.86 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sv/documents/overview/leganto-epar-summary-public_sv.pdf)

## Product information

Leganto : EPAR - Product Information

English (EN) (1.68 MB - PDF)

**First published:** 23/06/2011

**Last updated:** 18/02/2022

[View](/en/documents/product-information/leganto-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-620)

български (BG) (5.74 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/bg/documents/product-information/leganto-epar-product-information_bg.pdf)

español (ES) (1.76 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/es/documents/product-information/leganto-epar-product-information_es.pdf)

čeština (CS) (4.56 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/cs/documents/product-information/leganto-epar-product-information_cs.pdf)

dansk (DA) (1.72 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/da/documents/product-information/leganto-epar-product-information_da.pdf)

Deutsch (DE) (1.84 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/de/documents/product-information/leganto-epar-product-information_de.pdf)

eesti keel (ET) (1.78 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/et/documents/product-information/leganto-epar-product-information_et.pdf)

ελληνικά (EL) (7.09 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/el/documents/product-information/leganto-epar-product-information_el.pdf)

français (FR) (1.83 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fr/documents/product-information/leganto-epar-product-information_fr.pdf)

hrvatski (HR) (1.72 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/hr/documents/product-information/leganto-epar-product-information_hr.pdf)

íslenska (IS) (1.73 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/is/documents/product-information/leganto-epar-product-information_is.pdf)

italiano (IT) (2.19 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/it/documents/product-information/leganto-epar-product-information_it.pdf)

latviešu valoda (LV) (4.68 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lv/documents/product-information/leganto-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.95 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lt/documents/product-information/leganto-epar-product-information_lt.pdf)

magyar (HU) (4.47 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/hu/documents/product-information/leganto-epar-product-information_hu.pdf)

Malti (MT) (5.01 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/mt/documents/product-information/leganto-epar-product-information_mt.pdf)

Nederlands (NL) (1.99 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/nl/documents/product-information/leganto-epar-product-information_nl.pdf)

norsk (NO) (2.82 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/no/documents/product-information/leganto-epar-product-information_no.pdf)

polski (PL) (4.65 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pl/documents/product-information/leganto-epar-product-information_pl.pdf)

português (PT) (1.79 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pt/documents/product-information/leganto-epar-product-information_pt.pdf)

română (RO) (1.86 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/ro/documents/product-information/leganto-epar-product-information_ro.pdf)

slovenčina (SK) (4.71 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sk/documents/product-information/leganto-epar-product-information_sk.pdf)

slovenščina (SL) (4.52 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sl/documents/product-information/leganto-epar-product-information_sl.pdf)

Suomi (FI) (1.72 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fi/documents/product-information/leganto-epar-product-information_fi.pdf)

svenska (SV) (1.92 MB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sv/documents/product-information/leganto-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1963 14/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Leganto : EPAR - All Authorised presentations

English (EN) (588.64 KB - PDF)

**First published:** 23/06/2011

**Last updated:** 18/02/2022

[View](/en/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-616)

български (BG) (630.41 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/bg/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_bg.pdf)

español (ES) (592.11 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/es/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_es.pdf)

čeština (CS) (650.15 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/cs/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (583.3 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/da/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (584.81 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/de/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (591.14 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/et/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (640.5 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/el/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_el.pdf)

français (FR) (589.13 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fr/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (603.28 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/hr/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (589.12 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/is/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_is.pdf)

italiano (IT) (587.82 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/it/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (685.06 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lv/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (610.4 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/lt/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (666.67 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/hu/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (685.36 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/mt/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (588.11 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/nl/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (607.01 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/no/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_no.pdf)

polski (PL) (695.69 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pl/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_pl.pdf)

português (PT) (586.47 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/pt/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_pt.pdf)

română (RO) (604.1 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/ro/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (669.54 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sk/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (699.68 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sl/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (589.17 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/fi/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (593.5 KB - PDF)

**First published:**

23/06/2011

**Last updated:**

18/02/2022

[View](/sv/documents/all-authorised-presentations/leganto-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Leganto Active substance rotigotine International non-proprietary name (INN) or common name rotigotine Therapeutic area (MeSH)

- Restless Legs Syndrome
- Parkinson Disease

Anatomical therapeutic chemical (ATC) code N04BC09

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Leganto is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.

Leganto is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).

## Authorisation details

EMA product number EMEA/H/C/002380 Marketing authorisation holder

UCB Pharma S.A.

Allée de la Recherche 60

Opinion adopted 14/04/2011 Marketing authorisation issued 16/06/2011 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Leganto : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (823.14 KB - PDF)

**First published:** 02/04/2012

**Last updated:** 18/02/2022

[View](/en/documents/procedural-steps-after/leganto-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Leganto-H-C-PSUSA-00002667-201702 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/12301/2018

English (EN) (624.82 KB - PDF)

**First published:** 11/01/2018

**Last updated:** 18/02/2022

[View](/en/documents/scientific-conclusion/leganto-h-c-psusa-00002667-201702-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Leganto-H-C-2380-P46-017 : EPAR - Assessment Report

Adopted

English (EN) (2.1 MB - PDF)

**First published:** 07/10/2016

**Last updated:** 18/02/2022

[View](/en/documents/variation-report/leganto-h-c-2380-p46-017-epar-assessment-report_en.pdf)

Leganto- H-C-2380-PSUV-0013 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/714236/2014

English (EN) (623.8 KB - PDF)

**First published:** 06/02/2015

**Last updated:** 18/02/2022

[View](/en/documents/scientific-conclusion/leganto-h-c-2380-psuv-0013-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Leganto : EPAR - Public assessment report

Adopted

Reference Number: EMA/437167/2011

English (EN) (663.75 KB - PDF)

**First published:** 23/06/2011

**Last updated:** 18/02/2022

[View](/en/documents/assessment-report/leganto-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Leganto

Adopted

Reference Number: EMA/259223/2011

English (EN) (610.31 KB - PDF)

**First published:** 15/04/2011

**Last updated:** 18/02/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-leganto_en.pdf)

**This page was last updated on** 18/02/2022

## Share this page

[Back to top](#main-content)